217 related articles for article (PubMed ID: 15507522)
41. Role of human telomerase reverse transcriptase and telomeric-repeat binding factor proteins 1 and 2 in human hematopoietic cells.
Yamada K; Yajima T; Yagihashi A; Kobayashi D; Koyanagi Y; Asanuma K; Yamada M; Moriai R; Kameshima H; Watanabe N
Jpn J Cancer Res; 2000 Dec; 91(12):1278-84. PubMed ID: 11123427
[TBL] [Abstract][Full Text] [Related]
42. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines.
Rha SY; Izbicka E; Lawrence R; Davidson K; Sun D; Moyer MP; Roodman GD; Hurley L; Von Hoff D
Clin Cancer Res; 2000 Mar; 6(3):987-93. PubMed ID: 10741725
[TBL] [Abstract][Full Text] [Related]
43. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
Hu Y; Bobb D; He J; Hill DA; Dome JS
Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
[TBL] [Abstract][Full Text] [Related]
44. Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models.
Berardinelli F; Coluzzi E; Sgura A; Antoccia A
Mutat Res Rev Mutat Res; 2017 Jul; 773():204-219. PubMed ID: 28927529
[TBL] [Abstract][Full Text] [Related]
45. Telomeres and telomerase in human leukemias.
Shay JW; Werbin H; Wright WE
Leukemia; 1996 Aug; 10(8):1255-61. PubMed ID: 8709628
[TBL] [Abstract][Full Text] [Related]
46. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of telomerase recruitment and cancer cell death.
Nakashima M; Nandakumar J; Sullivan KD; Espinosa JM; Cech TR
J Biol Chem; 2013 Nov; 288(46):33171-80. PubMed ID: 24097987
[TBL] [Abstract][Full Text] [Related]
48. Telomeres and telomerase in hematologic neoplasia.
Ohyashiki JH; Sashida G; Tauchi T; Ohyashiki K
Oncogene; 2002 Jan; 21(4):680-7. PubMed ID: 11850796
[TBL] [Abstract][Full Text] [Related]
49. Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant.
Delhommeau F; Thierry A; Feneux D; Lauret E; Leclercq E; Courtier MH; Sainteny F; Vainchenker W; Bennaceur-Griscelli A
Oncogene; 2002 Nov; 21(54):8262-71. PubMed ID: 12447689
[TBL] [Abstract][Full Text] [Related]
50. Effect of telomerase inhibition on preclinical models of malignant rhabdoid tumor.
Hu Y; Bobb D; Lu Y; He J; Dome JS
Cancer Genet; 2014 Sep; 207(9):403-11. PubMed ID: 25441685
[TBL] [Abstract][Full Text] [Related]
51. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
Batova A; Shao LE; Diccianni MB; Yu AL; Tanaka T; Rephaeli A; Nudelman A; Yu J
Blood; 2002 Nov; 100(9):3319-24. PubMed ID: 12384433
[TBL] [Abstract][Full Text] [Related]
52. [Telomeres and telomerase in leukemias].
Werda L; Skotnicki AB
Przegl Lek; 1999; 56(10):668-70. PubMed ID: 10695383
[TBL] [Abstract][Full Text] [Related]
53. The level of telomere dysfunction determines the efficacy of telomerase-based therapeutics in a lung cancer cell line.
Pantic M; Zimmermann S; Waller CF; Martens UM
Int J Oncol; 2005 May; 26(5):1227-32. PubMed ID: 15809713
[TBL] [Abstract][Full Text] [Related]
54. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia.
Bechter OE; Eisterer W; Pall G; Hilbe W; Kühr T; Thaler J
Cancer Res; 1998 Nov; 58(21):4918-22. PubMed ID: 9810000
[TBL] [Abstract][Full Text] [Related]
55. MST-312 Alters Telomere Dynamics, Gene Expression Profiles and Growth in Human Breast Cancer Cells.
Gurung RL; Lim SN; Low GK; Hande MP
J Nutrigenet Nutrigenomics; 2014; 7(4-6):283-98. PubMed ID: 26022559
[TBL] [Abstract][Full Text] [Related]
56. Platinum(II) phenanthroimidazole G-quadruplex ligand induces selective telomere shortening in A549 cancer cells.
Mancini J; Rousseau P; Castor KJ; Sleiman HF; Autexier C
Biochimie; 2016 Feb; 121():287-97. PubMed ID: 26724375
[TBL] [Abstract][Full Text] [Related]
57. Telomeres, senescence, and hematopoietic stem cells.
Zimmermann S; Martens UM
Cell Tissue Res; 2008 Jan; 331(1):79-90. PubMed ID: 17960423
[TBL] [Abstract][Full Text] [Related]
58. The role of telomeres in Etoposide induced tumor cell death.
Jeyapalan J; Leake A; Ahmed S; Saretzki G; Tilby M; von Zglinicki T
Cell Cycle; 2004 Sep; 3(9):1169-76. PubMed ID: 15326395
[TBL] [Abstract][Full Text] [Related]
59. KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells.
Phatak P; Dai F; Butler M; Nandakumar MP; Gutierrez PL; Edelman MJ; Hendriks H; Burger AM
Clin Cancer Res; 2008 Jul; 14(14):4593-602. PubMed ID: 18628474
[TBL] [Abstract][Full Text] [Related]
60. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations.
Damle RN; Batliwalla FM; Ghiotto F; Valetto A; Albesiano E; Sison C; Allen SL; Kolitz J; Vinciguerra VP; Kudalkar P; Wasil T; Rai KR; Ferrarini M; Gregersen PK; Chiorazzi N
Blood; 2004 Jan; 103(2):375-82. PubMed ID: 14504108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]